Dennis Ballinger
Keine laufenden Positionen mehr
Profil
Dennis Ballinger worked as a Director of Cardiovascular Disease Research at Myriad Genetics, Senior Director of Functional Genomics at Nuvelo, Director of Product Development at Ingenuity Systems, and Vice President of Genomics at Perlegen Sciences and Complete Genomics.
Prior to his industry experience, he was an Assistant Professor at Cornell University and Sloan-Kettering Institute for Cancer Research.
Ballinger holds a doctorate from Massachusetts Institute of Technology and an undergraduate degree from The University of Colorado.
Ehemalige bekannte Positionen von Dennis Ballinger
| Unternehmen | Position | Ende |
|---|---|---|
Perlegen Sciences, Inc.
 Perlegen Sciences, Inc. Drugstore ChainsRetail Trade Perlegen Sciences, Inc. discovers and develops drugs. Its product pipeline consists of targeted drug candidates addressing type II diabetes and dyslipidemia markets. The company's products include PGX-510 and PGX-520. It operates in the United States, European Union, and Japan. Perlegen Sciences was co-founded by Brad A. Margus, David R. Cox, and Stephen P. A. Fodor in 2000 and is headquartered in Mountain View, CA | Corporate Officer/Principal | 01.01.2008 |
Ingenuity Systems, Inc.
 Ingenuity Systems, Inc. Information Technology ServicesTechnology Services Ingenuity Systems, Inc. provides intuitive web-based applications for quickly analyzing and accurately interpreting the biological meaning of genomics data. The company was founded in 1998 and is headquartered in Redwood City, CA. | Corporate Officer/Principal | 01.01.2001 |
| Nuvelo, Inc. | Corporate Officer/Principal | 01.01.1999 |
| MYRIAD GENETICS, INC. | Corporate Officer/Principal | 01.01.1998 |
| Sloan-Kettering Institute for Cancer Research | Corporate Officer/Principal | 01.01.1994 |
Ausbildung von Dennis Ballinger
| Massachusetts Institute of Technology | Doctorate Degree |
| The University of Colorado | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MYRIAD GENETICS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Complete Genomics, Inc.
 Complete Genomics, Inc. BiotechnologyHealth Technology Complete Genomics, Inc. develops and markets DNA sequencing technology. It provides complete genomics analysis platform, which combines its proprietary human genome sequencing technology with the company's advanced informatics and data management software. The firm offers innovative, end-to-end, outsourced service model to the customers with data. The company was founded by Clifford A. Reid, Radoje T. Drmanac, David Smith and Robert John Curson in 2006 and is headquartered in San Jose, CA. | Health Technology |
Perlegen Sciences, Inc.
Perlegen Sciences, Inc. Drugstore ChainsRetail Trade Perlegen Sciences, Inc. discovers and develops drugs. Its product pipeline consists of targeted drug candidates addressing type II diabetes and dyslipidemia markets. The company's products include PGX-510 and PGX-520. It operates in the United States, European Union, and Japan. Perlegen Sciences was co-founded by Brad A. Margus, David R. Cox, and Stephen P. A. Fodor in 2000 and is headquartered in Mountain View, CA | Retail Trade |
Ingenuity Systems, Inc.
Ingenuity Systems, Inc. Information Technology ServicesTechnology Services Ingenuity Systems, Inc. provides intuitive web-based applications for quickly analyzing and accurately interpreting the biological meaning of genomics data. The company was founded in 1998 and is headquartered in Redwood City, CA. | Technology Services |
| Nuvelo, Inc. | Health Technology |
| Sloan-Kettering Institute for Cancer Research |